Compare OMER & TIGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OMER | TIGR |
|---|---|---|
| Founded | 1994 | 2014 |
| Country | United States | Singapore |
| Employees | N/A | 1346 |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 772.8M | 852.4M |
| IPO Year | 2008 | 2018 |
| Metric | OMER | TIGR |
|---|---|---|
| Price | $8.82 | $4.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $32.50 | $14.20 |
| AVG Volume (30 Days) | 1.7M | ★ 6.9M |
| Earning Date | 05-14-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 98.15 | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $29,868,000.00 | N/A |
| Revenue This Year | N/A | $19.75 |
| Revenue Next Year | $233.22 | $5.95 |
| P/E Ratio | $16.42 | ★ $9.77 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.95 | $4.00 |
| 52 Week High | $17.65 | $13.55 |
| Indicator | OMER | TIGR |
|---|---|---|
| Relative Strength Index (RSI) | 24.11 | 37.64 |
| Support Level | $8.27 | $4.00 |
| Resistance Level | $12.06 | $11.15 |
| Average True Range (ATR) | 0.77 | 0.32 |
| MACD | -0.12 | 0.03 |
| Stochastic Oscillator | 40.39 | 37.31 |
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
UP Fintech Holding Ltd is an online brokerage firm focusing on Chinese investors. Its trading platform enables investors to trade in equities and other financial instruments on multiple exchanges of stocks and other derivatives. The company offers its customers brokerage and value-added services, including trade order placement and execution, margin financing, account management, investor education, community discussion, and customer support.